19:27 , Mar 29, 2019 |  BC Week In Review  |  Company News

Ares Life Sciences to take Stallergenes Greer private

Investment firm Ares Life Sciences agreed to take allergy company Stallergenes Greer private. Ares Life Sciences (Geneva, Switzerland) will pay Stallergenes Greer plc (Euronext:STLLF) €37 ($41.85) in cash per share to acquire the 16% of...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Greer Laboratories, Stallergenes, Ares Life Sciences deal

Greer Laboratories Inc. , Lenoir, N.C.   Stallergenes S.A. , Antony, France   Ares Life Sciences , Geneva, Switzerland   Business: Inflammation   Ares Life Sciences completed the formation of new subsidiary Ares Allergy Holding...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Greer Laboratories, Stallergenes, Ares Life Sciences deal

Ares Life Sciences will combine its majority-owned Stallergenes company and wholly owned Greer Laboratories subsidiary to form new subsidiary Ares Allergy Holding plc, which Ares plans on listing on Euronext Paris. Stallergenes’ shareholders will receive...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Ares Life Sciences management update

Ares Life Sciences , Geneva, Switzerland   Business: Finance   Transitioned: Rick Russell, CEO of Ares’ Allergy Holdings Inc. company, to president and CEO of Greer Laboratories Inc. , which Ares Life Sciences acquired; he...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Greer short ragweed sublingual allergen immunotherapy liquid: Phase III data

A double-blind, North American Phase III trial in 429 patients ages 18-55 with moderate to severe allergic rhinoconjunctivitis showed that once-daily RW-SAIL met the primary endpoint of reducing average TCS from baseline over the entire...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Stallergenes, Greer sales and marketing update

Stallergenes granted Greer exclusive, U.S. commercialization rights to Oralair , a sublingual therapy against five grass allergens. Stallergenes is eligible for regulatory and commercial milestones of up to $120 million, plus royalties and an undisclosed...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Albion, Ares Life Sciences deal

Investment group Ares completed its acquisition of Albion, including wholly owned subsidiary Greer Laboratories Inc. (Lenoir, N.C.). The companies could not be reached for details (see BioCentury, March 18). Albion Medical Holdings Inc. , Lenoir,...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Company News

Albion Medical Holdings Inc., Ares Life Sciences deal

Investment group Ares will acquire 100% of the share capital of Albion, including wholly owned subsidiary Greer Laboratories Inc. (Lenoir, N.C.). Greer recently completed a Phase III trial with its sublingual allergy immunotherapy liquid (SAIL)...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Company News

Stallergenes, Ares Life Sciences deal

Investment firm Ares increased its stake in Stallergenes to 73.2% from 68% for an undisclosed sum after the close of its mandated offer in compliance with European law for the remaining stake of Stallergenes it...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

Stallergenes, Ares Life Sciences inflammation news

Investment firm Ares re-opened its mandated offer in compliance with European law for the remaining stake of Stallergenes it does not own for €59 per share, or €424.5 million ($581.5 million). The price is a...